EP2900293A1 - Système de traitement de plaies - Google Patents
Système de traitement de plaiesInfo
- Publication number
- EP2900293A1 EP2900293A1 EP13722291.5A EP13722291A EP2900293A1 EP 2900293 A1 EP2900293 A1 EP 2900293A1 EP 13722291 A EP13722291 A EP 13722291A EP 2900293 A1 EP2900293 A1 EP 2900293A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- negative pressure
- wound
- therapy
- therapeutic treatment
- wound dressing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 443
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 443
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 241
- 238000011282 treatment Methods 0.000 claims abstract description 155
- 229920000642 polymer Polymers 0.000 claims abstract description 102
- 229920000247 superabsorbent polymer Polymers 0.000 claims abstract description 47
- 230000001225 therapeutic effect Effects 0.000 claims description 118
- 230000002745 absorbent Effects 0.000 claims description 85
- 239000002250 absorbent Substances 0.000 claims description 85
- 239000000463 material Substances 0.000 claims description 45
- 241001465754 Metazoa Species 0.000 claims description 43
- 239000006260 foam Substances 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 238000007789 sealing Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 238000004891 communication Methods 0.000 claims description 9
- 230000000845 anti-microbial effect Effects 0.000 claims description 8
- 229920005830 Polyurethane Foam Polymers 0.000 claims description 7
- 239000011496 polyurethane foam Substances 0.000 claims description 7
- 239000004753 textile Substances 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000009827 uniform distribution Methods 0.000 claims description 4
- 229920003043 Cellulose fiber Polymers 0.000 claims description 3
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 206010063560 Excessive granulation tissue Diseases 0.000 description 17
- 210000001126 granulation tissue Anatomy 0.000 description 17
- 239000002245 particle Substances 0.000 description 16
- -1 polypropylene Polymers 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 229920000058 polyacrylate Polymers 0.000 description 15
- 239000000835 fiber Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000000638 stimulation Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 229910052709 silver Inorganic materials 0.000 description 10
- 239000004332 silver Substances 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 8
- 239000004604 Blowing Agent Substances 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000004814 polyurethane Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010029113 Neovascularisation Diseases 0.000 description 6
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 229920001155 polypropylene Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 4
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229920005906 polyester polyol Polymers 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 239000005056 polyisocyanate Substances 0.000 description 4
- 229920001228 polyisocyanate Polymers 0.000 description 4
- 229940123208 Biguanide Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 3
- 229920002413 Polyhexanide Polymers 0.000 description 3
- 239000002313 adhesive film Substances 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 239000002657 fibrous material Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000007655 standard test method Methods 0.000 description 3
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 3
- 229920003176 water-insoluble polymer Polymers 0.000 description 3
- OVBFMUAFNIIQAL-UHFFFAOYSA-N 1,4-diisocyanatobutane Chemical compound O=C=NCCCCN=C=O OVBFMUAFNIIQAL-UHFFFAOYSA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000018803 Calgranulin A Human genes 0.000 description 2
- 108010052500 Calgranulin A Proteins 0.000 description 2
- 102000018755 Calgranulin B Human genes 0.000 description 2
- 108010052495 Calgranulin B Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920000538 Poly[(phenyl isocyanate)-co-formaldehyde] Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- 239000012891 Ringer solution Substances 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229920003064 carboxyethyl cellulose Polymers 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000009581 negative-pressure wound therapy Methods 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 229920006264 polyurethane film Polymers 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 238000009489 vacuum treatment Methods 0.000 description 2
- 230000007998 vessel formation Effects 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- MOJYDLJMKAMQDC-UHFFFAOYSA-N 2-phenyl-1h-imidazol-5-amine Chemical class N1C(N)=CN=C1C1=CC=CC=C1 MOJYDLJMKAMQDC-UHFFFAOYSA-N 0.000 description 1
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 206010050502 Neuropathic ulcer Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 150000003868 ammonium compounds Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- HIFVAOIJYDXIJG-UHFFFAOYSA-N benzylbenzene;isocyanic acid Chemical class N=C=O.N=C=O.C=1C=CC=CC=1CC1=CC=CC=C1 HIFVAOIJYDXIJG-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- PASCYLAFGHJSHW-UHFFFAOYSA-N ethyl 2-[(4-methoxyphenyl)methyl]-3-(methylamino)propanoate Chemical compound CCOC(=O)C(CNC)CC1=CC=C(OC)C=C1 PASCYLAFGHJSHW-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- ZVXNYZWXUADSRV-UHFFFAOYSA-N octenidine Chemical compound C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 ZVXNYZWXUADSRV-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229940093158 polyhexanide Drugs 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 239000004447 silicone coating Substances 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960004267 taurolidine Drugs 0.000 description 1
- AJKIRUJIDFJUKJ-UHFFFAOYSA-N taurolidine Chemical compound C1NS(=O)(=O)CCN1CN1CNS(=O)(=O)CC1 AJKIRUJIDFJUKJ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical class [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/05—Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/88—Draining devices having means for processing the drained fluid, e.g. an absorber
- A61M1/882—Draining devices provided with means for releasing antimicrobial or gelation agents in the drained fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/915—Constructional details of the pressure distribution manifold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61D1/00—Surgical instruments for veterinary use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00217—Wound bandages not adhering to the wound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00727—Plasters means for wound humidity control
- A61F2013/00748—Plasters means for wound humidity control with hydrocolloids or superabsorbers
- A61F2013/00753—Plasters means for wound humidity control with hydrocolloids or superabsorbers superabsorbent fabric of cloth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/916—Suction aspects of the dressing specially adapted for deep wounds
Definitions
- the invention relates generally to wound therapy, and more particularly to devices or systems for wound therapy.
- Negative wound therapy also known as topical negative pressure (TNP), negative pressure wound therapy (NPWT) or vacuum assisted closure (VAC), has long been recognized, but has been particularly prevalent since the mid-term / Late 1990s increasingly used.
- TNP topical negative pressure
- NPWT negative pressure wound therapy
- VAC vacuum assisted closure
- a wound filling material is usually inserted into the wound, the wound area is covered with a foil and a negative pressure is generated in the wound space by means of a drainage tube and a vacuum pump.
- the negative pressure causes effective wound cleansing by removing wound exudate.
- Further advantages include promotion of granulation tissue formation and reduction of wound edema formation.
- vacuum assisted closure treatment already suggests, negative pressure therapy is usually performed until the wound is closed. Wound closure is generally considered to be achieved when there is a layer of epidermis over the former wound site. Wound closure can be achieved through healing processes or through surgical procedures.
- Low pressure therapy is particularly useful in acute or chronic wounds such as ulcers (e.g., pressure ulcers, diabetic, neuropathic or venous ulcers), traumatic wounds, refractory wounds, infected wounds, postoperative wounds, probed fistulas, and skin flaps and skin grafts.
- Chronic wounds are characterized by slow or absent wound healing.
- WO 1993/009727 A1 describes a device for promoting wound healing by the application of negative pressure on the area of the skin having the wound and surrounding the wound.
- the device according to WO 1993/009727 AI comprises a vacuum device for generating the negative pressure, an airtight covering of the wound, which is in a functional connection with the vacuum device, and a wound dressing for positioning on the wound inside the airtight cover.
- the wound dressing is preferably an open-cell polymer foam, for example polyester foam.
- open cell polymer foam for example polyester foam.
- Wound wound therapy devices are also commercially available, ranging from small, portable devices that allow patients some mobility, to stationary devices, such as in long-term care facilities.
- the object of the present invention is to provide a wound therapy which positively influences the physiological condition of the wound. Furthermore, a wound therapy should be provided, which affects the patient as little as possible. In addition, it was an object to improve the cost of wound therapy, but without compromising the clinical efficiency of wound therapy, or even increasing clinical efficiency, or providing systems that allow for such improved wound therapy.
- the impairment of the patient compared to the conventional negative pressure therapy could be improved, especially with regard to the pain sensation and the mobility of the patient.
- the invention according to a first aspect comprises a negative pressure therapy device for use in a wound therapy, which comprises a first therapy section, in which negative pressure therapy is performed by means of the negative pressure therapy device, and a subsequent second therapy section, in which uses the wound therapy a wound dressing is carried out without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
- the invention relates to a product for use in the therapeutic treatment of wounds on the human or animal body, the product comprising a negative pressure therapy device, characterized in that the therapeutic treatment comprises a first therapy section in which the negative pressure therapy by means of the negative pressure therapy device is performed, and a subsequent second therapy section, in which the therapeutic treatment is performed using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent body which comprises a swellable polymer, in particular a superabsorbent polymer.
- the product or the negative pressure therapy device is therefore claimed explicitly in connection with its specific medical application or indication, namely the therapeutic treatment of wounds, which is based on the special new therapeutic application or the special new treatment plan, which / two successive Therapy sections includes.
- the product may consist solely of the negative pressure therapy device.
- wound therapy and therapeutic treatment of wounds are hereby used interchangeably. It can wounds on the human or animal body are treated, preferably the treatment takes place on the human body.
- a negative pressure therapy device is a device for negative pressure therapy of wounds.
- the present invention further includes the use of a negative pressure therapy device in the therapeutic treatment of wounds on the human or animal body, characterized in that the therapeutic treatment comprises a first therapy section, in which the negative pressure therapy is performed by means of the device, and that the therapeutic treatment a subsequent second treatment section, which is performed using a wound dressing without generating a negative pressure, wherein in the second therapy section, a wound dressing is used, which contains a absorbent body comprising a swellable polymer, in particular a superabsorbent polymer.
- the invention provides a wound dressing for use in a wound therapy, comprising a first therapy section, in which wound therapy is performed under negative pressure, and a subsequent second therapy section, in which wound therapy using the wound dressing without producing a wound therapy Underpressure, preferably in moist or moist wet environment, is performed.
- the wound dressing is preferably intended specifically for use in wound therapy in a moist or wet-moist environment.
- the invention relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section in which a wound therapy is performed by means of negative pressure, and a subsequent second treatment section, in which the therapeutic treatment is performed using the wound dressing without generating a negative pressure.
- the wound dressing herein is expressly claimed in the context of its specific medical application or indication, namely, the therapeutic treatment of wounds based on the particular new therapeutic mode of administration or the particular new therapy regimen, which are two consecutive includes the following therapy sections.
- the second aspect of the invention relates to a product for use in the therapeutic treatment of wounds on the human or animal body, the product comprising a wound dressing, and wherein the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent Polymer, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and a subsequent second therapy section, in which the therapeutic treatment using the wound dressing without generating a negative pressure is carried out.
- the product may consist solely of the wound dressing.
- the present invention further encompasses the use of a wound dressing in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and in that the therapeutic treatment comprises a subsequent second treatment section, which is performed using the wound dressing without generating a negative pressure.
- the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and in that the therapeutic treatment comprises a subsequent second treatment section, which is performed using the wound dressing without generating a negative pressure.
- the invention provides a combination of apparatus for performing wound therapy by means of negative pressure and wound dressing for application in a wound therapy comprising a first therapy section, in which wound therapy is performed using the device under negative pressure, and a subsequent one Second therapy section comprises, in which wound therapy using the wound dressing without generating a negative pressure, preferably in a moist or wet-wet environment, is performed, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
- the third aspect of the invention relates to a product for use in the therapeutic treatment of wounds on the human or animal body, the product comprising a device for negative pressure therapy of wounds and a wound dressing, and wherein the wound dressing comprises an absorbent body which a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first treatment section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and a subsequent second therapy section, in which the therapeutic treatment Use of the wound dressing is carried out without generating a negative pressure.
- the combination or the product is expressly claimed in connection with their specific medical application or indication, namely the therapeutic treatment of wounds, which comprises two successive therapy sections.
- the present invention further comprises the use of a combination of a device for negative pressure therapy of wounds and a wound dressing in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device for negative pressure therapy of wounds, and one thereon following second therapy section, in which the therapeutic treatment is performed using the wound dressing without generating a negative pressure.
- a further subject of the invention is a method for the therapeutic treatment of wounds on the human or animal body, comprising i) a first therapy section, in which negative pressure therapy is carried out by means of a device for negative pressure therapy of wounds,
- a subsequent second treatment section in which the therapeutic treatment (preferably in a moist or wet-moist environment) is carried out using a second wound dressing without generating a negative pressure
- the second wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer.
- the first wound dressing is preferably a wound dressing which comprises an open-cell foam, for example an open-celled polyurethane foam.
- an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
- the invention also relates, in particular, to a method for the therapeutic treatment of wounds on the human or animal body i) a first therapy section, in which negative pressure therapy is carried out by means of a device for negative pressure therapy of wounds for combating inflammation and / or edema mobilization in the wound area, wherein the device for performing wound therapy by means of negative pressure
- the second wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer.
- the subject matter of the invention is a combination of a device for negative pressure therapy of wounds and a wound dressing (the combination being provided) for use in the therapeutic treatment of wounds on the human or animal body, the wound dressing comprising an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device, and a subsequent second therapy section, in which the therapeutic treatment is performed using the wound dressing without creating a negative pressure becomes.
- the invention according to the first aspect therefore provides:
- An open-cell foam for use in the therapeutic treatment of wounds on the human or animal body characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a negative pressure therapy device comprising the open-cell foam, and comprises a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
- the invention according to the first aspect provides
- a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of a negative pressure therapy device comprising the swellable polymer, and comprises a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
- the invention relates in this first aspect:
- an open-cell foam for the preparation of a vacuum device for use in the therapeutic treatment of wounds on the human or animal body, characterized in that the therapeutic treatment comprises a first therapy section, in which the negative pressure therapy is performed by means of the open-cell foam negative pressure therapy device, and a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
- the open-cell foam is used in particular for producing a wound dressing of the vacuum device.
- the invention according to the alternative embodiment relates to: The use of a swellable polymer for the production of a vacuum device for use in the therapeutic treatment of wounds on the human or animal body, characterized in that the therapeutic treatment comprises a first treatment section, in which negative pressure therapy is performed by means of the swelling polymer comprising the vacuum device, and a following second treatment section, in which the therapeutic treatment is performed using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent body, which comprises a swellable polymer, in particular a superabsorbent polymer.
- the swellable polymer is used in particular for producing a wound dressing of the vacuum device.
- the invention according to the second aspect therefore provides:
- a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body wherein the swellable polymer is preferably contained in an absorbent and this preferably in a wound dressing, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy a device for negative pressure therapy of wounds is performed, and a subsequent second treatment section comprises, in which the therapeutic treatment using the swellable polymer or preferably using the swellable polymer containing the absorbent body or preferably using the swellable polymer containing in The absorbent pad contained in the wound dressing is carried out without generating a negative pressure. Accordingly also provided:
- An absorbent body for use in the therapeutic treatment of wounds on the human or animal body wherein the absorbent body comprises a swellable polymer, in particular a superabsorbent polymer, and is preferably contained in a wound dressing, characterized in that the therapeutic treatment comprises a first therapy section, in which a wound therapy is performed by means of negative pressure, and a subsequent second treatment section, in which the therapeutic treatment is carried out using the absorbent body without generating a negative pressure.
- the invention under this second aspect also relates to:
- a swellable polymer for the production of an absorbent body for use in the therapeutic treatment of wounds on the human or animal body, wherein the absorbent body is preferably contained in a wound dressing, characterized in that the therapeutic treatment comprises a first therapy section in which negative pressure therapy by means of a A device for negative pressure therapy of wounds is performed, and a subsequent second therapy section, in which the therapeutic treatment using the swellable polymer-containing absorbent body is carried out without generating a negative pressure.
- the subject matter of the invention is also a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer in that the wound dressing is used when the inflammatory phase subsides after a previous negative-pressure therapy.
- the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer in that the wound dressing is used when the inflammatory phase subsides after a previous negative-pressure therapy.
- the invention also relates to a swellable polymer, preferably contained in a wound dressing, for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent body in the wound dressing, characterized in that the swellable Polymer or the wound dressing is used on decay of the inflammatory phase after a previous negative pressure therapy or the corresponding use of a swellable polymer in the preparation of this wound dressing.
- the subject of the invention is also a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, the wound dressing comprising a absorbent body comprising a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing in a second
- the first phase of therapy comprises a negative pressure therapy by means of a device for negative pressure therapy of wounds and wherein the second therapy phase is carried out using the wound dressing without generating a negative pressure.
- the terms "therapy section” and “therapy phase” are used synonymously here.
- the invention also relates to a swellable polymer, preferably in a wound dressing, for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent body in the wound dressing, characterized in that the swellable polymer or the wound dressing is used in a second therapy phase after a first therapy phase aimed at combating inflammation and / or edema, wherein the first therapy phase comprises a negative pressure therapy by means of a device for negative pressure therapy of wounds and wherein the second therapy phase using the swellable polymer or the Wound dressing is performed without generating a negative pressure. or the corresponding use of a swellable polymer in the manufacture of this wound dressing.
- the invention furthermore relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing is used for increased stimulation of the formation of Granulation tissue is used in the wound area after a previous negative pressure therapy.
- the invention also relates to the use of such a wound dressing for increased stimulation of the formation of granulation tissue in the wound area after a previous negative pressure therapy in the therapeutic treatment of wounds on the human or animal body.
- the invention thus also provides a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent in a wound dressing, characterized in that the swellable polymer or the wound dressing to reinforced Stimulation of the formation of granulation tissue in the wound area after a previous negative pressure therapy is used or the corresponding use.
- the invention furthermore relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing is used for increased stimulation of the Neovascularization in the wound area after a previous negative pressure therapy is used.
- the invention also relates to the use of such a wound dressing for increased stimulation of vessel formation in the wound area after a previous negative pressure therapy in the therapeutic treatment of wounds on the human or animal body.
- the invention thus also provides a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent in a wound dressing, characterized in that the swellable polymer or the wound dressing to reinforced Stimulation of neovascularization in the wound area is used after a previous negative pressure therapy; or the corresponding use of the swellable polymer.
- the invention furthermore relates to a wound dressing for use in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the wound dressing increases the fibroblast density in the superficial granulation tissue of a wound after a previous negative pressure therapy is used.
- the wound dressing also relates to the use of such a wound dressing for increasing the fibroblast density in the superficial granulation tissue of a wound after a previous negative pressure therapy in the therapeutic treatment of wounds on the human or animal body.
- the invention thus also provides a swellable polymer for use in the therapeutic treatment of wounds on the human or animal body, wherein the swellable polymer is preferably contained in a absorbent in a wound dressing, characterized in that the swellable polymer or the wound dressing to increase the fibroblast density is used in the superficial granulation tissue of a wound after a previous negative pressure therapy; or the corresponding use.
- the literature describes three major healing phases of a wound, especially in wounds with tissue loss.
- phase 1 inflammatory or exudative phase for haemostasis and wound cleansing
- phase 2 proliferative phase for the formation of granulation tissue
- phase 3 epithelization phase
- the inflammatory phase usually occurs immediately after wound formation. It is characterized by vascular constriction, activation of the coagulation cascade and complex immunological processes. The release of chemically attractive substances (e.g., chemokines) can cause a local inflammatory response. There are four main signs of inflammation: edema, exudation, redness and pain. The surrounding vessels can expand and inflammatory cells migrate into the site of inflammation. These can eliminate microorganisms and tissue necroses. This can be done a cleaning of the wound.
- chemically attractive substances e.g., chemokines
- the first treatment section preferably comprises only the inflammatory phase or part of the inflammatory phase.
- the first therapy section preferably extends to the decay or completion of the inflammatory phase.
- the decay of the inflammatory phase is recognizable to the physician as the disappearance of one or more of the inflammatory symptoms: edema, exudation, redness and pain.
- the first treatment section is terminated before a visible granulation is recognizable.
- the duration of the first part of the therapy depends on the individual circumstances. However, successes have already been achieved when the first treatment section extends over a period of only 1, 2, 3, 4, 5, 6, 7 or 8 days, e.g. between 3 and 7 or 4 and 6 days, especially 4 days. This period of time is shorter than the typical duration of a negative pressure therapy. In particular, the negative pressure therapy no longer needs to be performed until the wound closure.
- the second therapy section is also to be adapted to individual circumstances, but may, for example, advantageously over a period of 1 to 1000 days, preferably from two to one hundred days, e.g. three to twenty days, especially four to ten days.
- the second therapy section directly follows the first therapy section.
- the device to be used according to the invention for carrying out wound therapy by means of negative pressure may be a device known from the prior art.
- the device for carrying out the negative pressure therapy (a) an air-impermeable cover material for airtight sealing of wound and wound environment, whereby a wound space is formed,
- a wound dressing which preferably comprises an open-celled foam.
- the vacuum therapy device which can be used according to the invention comprises a covering material (a) for the airtight sealing of the wound.
- a covering material for the airtight sealing of the wound.
- Airtight sealing is not to be understood here as meaning that no gas exchange takes place between the wound space and its surroundings. Rather, by “airtight sealing” in this context is meant that the vacuum necessary for the negative pressure therapy can be maintained. It can therefore also be used covering materials which have a slight gas permeability, as long as necessary for the negative pressure vacuum can be maintained.
- the airtight cover material may be in the form of, for example, a shell made of a solid material or in the form of a flexible film. Also conceivable are combinations of these.
- the covering material for airtight sealing of the wound comprises a water-insoluble polymer or a metal foil.
- the cover material preferably has a thickness of 10 ⁇ m to 10,000 ⁇ m, in particular of 25 ⁇ m to 100 ⁇ m.
- the covering material (a) is a water-insoluble polymer.
- the water-insoluble polymer preferably has a solubility of 10 mg / l or less, more preferably of 1 mg / ml or less, in particular of 0.0001 to 1 mg / ml (determined in accordance with the column elution method according to EU guideline RL67-548-EWG, Annex V, Chapter A6).
- Examples are polyurethane, polyester, polypropylene, polyethylene, polyamide or polyvinyl chloride, polyorganosiloxane (silicone), or a mixture thereof.
- the polymers mentioned are preferably present in non-cellular form.
- the cover material has a water vapor permeability of 100 to 2500 g / mx 24, more preferably from 500 to 2000 g / m 2 x 24h, even more preferably from 800 to 1,600 g / m 2 x 24 h, in particular 1050 to 1450 g / m 2 x 24 h, determined according to DIN EN 13726-2 at 23 ° C and 85% relative humidity, on.
- cover material and finished products can be used which have the aforementioned properties.
- the polyurethane film of the brand Hydrofilm® (Paul Hartmann AG, Germany) or Visulin® (Paul Hartmann AG, Germany) has proven to be a suitable covering material for the vacuum therapy device to be used according to the invention.
- the cover material is usually attached in the wound environment or at the wound edge so that an airtight wound closure is ensured. It may be expedient if the cover material is fully self-adhesive or has a self-adhesive edge. Alternatively, attachment and sealing can be done, for example, with an adhesive film, with a liquid adhesive or with a sealing compound. However, it is also possible that the covering material is held only by the negative pressure generated during the vacuum treatment at the wound.
- the device for negative pressure therapy to be used according to the invention comprises a means (b) for providing fluid communication between the wound space and a negative pressure source located outside the covering material, so that a negative pressure can be produced in the wound space and liquid can be sucked out of the wound space.
- negative pressure in the wound space in the context of the invention means a reduced air pressure within the wound dressing compared to the ambient air pressure (atmospheric air pressure).
- within the wound dressing is meant the space formed by the covering material and the wound.
- Negative pressure is often referred to as “negative pressure”.
- the fluid communication can be made for example with a connection line and / or with a vacuum fitting. Vacuum fittings are known in the art as "port”.
- the means for the functional connection of the wound space with a vacuum source located outside the covering material is at least one connecting line.
- the at least one connecting line can be passed through the covering material.
- the at least one connecting line can be carried out under the edge of the covering material.
- the passage point must be hermetically sealed, so that the desired negative pressure in the dressing can be maintained.
- a sealant for example, an adhesive film, an adhesive, or an adhesive strip is suitable.
- the connection line can be, for example, a hose, a pipe or another body with a cavity.
- a suitable tube is, for example, a silicone drainage tube.
- the means for operatively connecting the wound space to a source of negative pressure external to the cover material is a vacuum connector (port) which can be secured to one of the inner or outer sides of the cover material, the cover material having suitable openings having.
- a vacuum connector port
- the seal can be made for example with an adhesive film, with an adhesive, or with an adhesive strip.
- the port itself has corresponding fastening devices, such as adhesive surfaces, grouted.
- the cover material (a) and the means for providing fluid communication between the wound space and a vacuum source (b) located outside the cover material are already provided ready for use interconnected.
- the inventive device for negative pressure therapy nor component (c), the wound dressing, the open-cell foam comprises or consists of this.
- open-celled means that in the foam (c) at least 60% open cells, preferably at least 90% open cells, more preferably at least 98% open cells, in particular substantially 100% open cells, based on the total number of cells , available.
- the wound dressing (c) of the vacuum device for example, also allows a substantially even distribution of the negative pressure in the wound space.
- the open-cell foam to be used according to the invention is a polyurethane foam obtainable by reacting a mixture comprising the components (i) polyisocyanate, (ii) polyol, preferably polyester polyol, (iii) blowing agent, and (iv) catalyst.
- polyisocyanates As polyisocyanates (i-PUR) it is possible to use generally known aliphatic, cycloaliphatic and / or especially aromatic polyisocyanates become.
- diphenylmethane diisocyanate (MDI), in particular 4,4'-diphenylmethane diisocyanate (4,4'-MDI), mixtures of monomeric diphenylmethane diisocyanates and higher-nuclear homologues of diphenylmethane diisocyanate (PMDI), tetramethylene diisocyanate (TMDI), are suitable for the preparation of the polyurethanes.
- PMDI diphenylmethane diisocyanate
- TMDI tetramethylene diisocyanate
- HDI Hexamethylene diisocyanate
- TDI tolylene diisocyanate
- polyesterols As isocyanate-reactive compounds (ii-PUR), polyols such as polyetherols and / or polyesterols are usually used. Polyester polyols are preferably used in the component (ii-PUR).
- the polyesterols (II-PUR) used are generally prepared by condensation of polyfunctional alcohols, preferably diols, having 2 to 12 carbon atoms, preferably 2 to 6 carbon atoms, with polyfunctional carboxylic acids having 2 to 12 carbon atoms, preferably 4 to 8 carbon atoms. Examples of suitable acids are succinic acid, glutaric acid, adipic acid, phthalic acid, isophthalic acid, and / or terephthalic acid and mixtures thereof. Adipic acid is particularly preferred.
- dihydric and polyhydric alcohols examples include ethanediol, diethylene glycol, 1, 4-butanediol, 1, 5-pentanediol, and / or 1, 6-hexanediol and mixtures thereof. 1,4-butanediol is particularly preferred.
- the compounds (ii-PUR) may be used in admixture with chain extenders and / or crosslinkers.
- catalysts (iv-PUR) it is possible to use compounds which accelerate the reaction of component (i-PUR) with component (ii-PUR).
- tertiary amines and / or organic metal compounds in particular tin compounds.
- the following compounds can be used as catalysts: triethylenediamine, aminoalkyl and / or aminophenylimidazoles and / or tin (II) salts of organic carboxylic acids.
- Catalysts are generally used in an amount of 0.1 to 5 wt .-% based on the weight of the component (ii-PUR).
- blowing agent iii-PUR
- blowing agent iii-PUR
- a physically acting propellant water may preferably be used, which forms by reaction with the isocyanate groups carbon dioxide.
- physical blowing agents are (cyclo) aliphatic hydrocarbons, preferably those having 4 to 8, more preferably 4 to 6 and especially 5 carbon atoms, partially halogenated hydrocarbons or ethers, ketones or acetates. The amount of blowing agent used depends on the desired density of Foams. The different blowing agents can be used individually or in any mixtures with each other.
- blowing agent generally in an amount of 0.1 to 5 wt .-%, in particular from 2.5 to 4 wt .-%, based on the weight of component (ii-PUR).
- Physical blowing agents are preferably used in an amount of ⁇ 0.5% by weight, based on the weight of component (II-PUR).
- the reaction is optionally carried out in the presence of (v-PUR) auxiliaries and / or additives, such as.
- auxiliaries such as.
- the open-celled polyurethane foam is obtainable by reacting a mixture comprising or consisting of the following components:
- polyester polyol wherein the polyester polyol is preferably obtainable by reacting a dicarboxylic acid having 4 to 8 carbon atoms with a dialcohol having 2 to 6 carbon atoms and / or preferably one weight average molecular weight of 500 to 4000 g / mol, (iii) blowing agent, and (iv) catalyst.
- the open-cell foam, in particular polyurethane foam, after three days of storage in bovine serum has a tensile strength between 80 kPa and 300 kPa, measured according to DIN 53571.
- the open-cell foam in particular polyurethane foam, an air permeability of 1000 to 8000 l / (m 2 sec), measured according to DIN EN ISO 9237.
- the wound dressing (c) of the vacuum device silver in the form of silver ions or in the form of atomic silver contain.
- silver is applied in the form of a silver coating on the wound dressing.
- the silver may be distributed within the wound dressing.
- the foam (c) contains 0.000001 to 0.1% by weight, more preferably 0.0001 to 0.01% by weight of silver, based on the total weight of the foam (c).
- the wound dressing (c), in particular the open-cell foam has a thickness of 1 to 50 mm, in particular 15 mm to 30 mm.
- the device for negative pressure therapy of wounds comprises at least one wound contact layer for introduction between wound dressing (c) and wound surface.
- the additional wound contact layer may be adhesively or non-adhesively bonded to the wound dressing (c).
- any wound contact layer known from the prior art may be considered wound contact layer as long as, on the one hand, passage of wound exudate is ensured and, on the other hand, the material has no tendency to coalesce or adhere to the wound tissue.
- Especially suitable wound contact layers are ointment of Hydrotul ® brand Atrauman ® and Atrauman Ag ® (Paul Hartmann AG, Germany).
- devices for negative pressure therapy of wounds can be used which (as wound dressing (c)) contains an open-celled foam based on a crosslinked polyorganosiloxane.
- wound dressing (c) contains an open-celled foam based on a crosslinked polyorganosiloxane.
- An advantage of the open-celled foam based on a crosslinked polyorganosiloxane is that it provides a soft wound dressing for the negative pressure therapy of wounds and ensures a uniform pressure distribution on the wound base. By providing a soft wound dressing and even pressure distribution, the vacuum treatment can be carried out gently and effectively.
- the device for negative pressure therapy of wounds comprises at least one additional pressure distribution layer between the wound dressing (c) and the covering material (a).
- the advantage of an additional pressure distribution layer may be that the pressure exerted by the dressing on the wound base is more evenly distributed by the use of the pressure distribution layer.
- the pressure distribution layer can store and / or forward additional wound exudate.
- the additional pressure distribution layer may be an open cell or semi-open cell foam, a spacer fabric, a textile layer, a structured gel, or a permeable nonwoven layer.
- Suitable textile layers include ES compresses or lattice garb.
- the additional pressure distribution layer may be configured such that fluid, such as wound exudate, is passed therethrough. This can be the Pressure distribution layer containing suitable channels or openings, or consist of a liquid-permeable material.
- first wound dressing is basically not to be confused with the wound dressing for wound therapy according to the invention, which is used in the second therapy section and is described in more detail below (“second wound dressing”). It is noted, however, that the wound dressings described below are in principle also suitable as wound dressings (c) and are correspondingly included in the present invention.
- the second treatment section is generally performed "without negative pressure". It is not to be understood that a wound treatment with vacuum device, however, is carried out without applied negative pressure. Rather, it is to be understood that the use of a vacuum device is completely dispensed with in the second therapy section.
- the wound dressing (“second wound dressing”) is generally a wound dressing which allows wound treatment in a moist or moist environment, moist or moist wet means that the wound under the wound dressing has a moist or moist surface, ie the wound does not dry (at least not completely) below the surface
- the wound dressing (“second wound dressing”) comprises an absorbent body which comprises a swellable polymer, in particular a superabsorbent polymer.
- the wound dressing comprises an absorbent which comprises an at least partially liquid-permeable cover and, arranged therein, a swellable polymer, in particular a superabsorbent polymer.
- a swellable polymer in particular a superabsorbent polymer.
- the swellable polymer is surrounded by the shell.
- the at least partially liquid-permeable casing allows the passage of liquids over its entire surface or at least in certain areas of the shell.
- the shell may consist of a single material or include several materials.
- the sheath may advantageously be or comprise a textile (surface) material, such as a knitted fabric, a knitted fabric or a woven fabric, in particular of polyolefin, in particular of polypropylene.
- the sheath can advantageously at least partially consist of a textile surface which is non-elastically extensible in the longitudinal, transverse and diagonal directions, as disclosed in EP 0 594 034.
- the swellable polymer to be used in the invention is or preferably comprises a superabsorbent polymer.
- a superabsorbent polymer (SAP) is generally understood to mean a water-insoluble, swellable polymer which can take up many times its own weight of liquid, for example water. The fluid intake leads to the formation of a hydrogel.
- the term superabsorbent polymer is understood in particular to mean a polymer which according to the standard test method WSP 240.2 (05) has a free swell capacity of at least 10 g / g, preferably at least 20 g / g having.
- WSP 240.2 (05) for determining the w value is described in "Standard Test Methods for the Nonwoven and Related Industries", Edition 2008 (edited by "EDANA, International Association Serving the Nonwoven and Related Industries", Cary, NC, USA and “INDA, Association of the Nonwovens Fabrics Industry", Brussels, Belgium).
- WSP 240.2 (05) according to EDANA is a standard test method for determining the w value ("free swell capacity") of superabsorbent polyacrylate powder. According to WSP 240.2 (05), the free uptake capacity for a 0.9 weight percent saline solution is determined.
- the determination of the w value of superabsorbent material which is not polyacrylate powder is carried out in a corresponding manner.
- the sup ⁇ erabsorb Schlierende polymer may be in the form of fibers or particles preferably.
- the term "swellable polymer” preferably refers to polymers which are in principle capable of swelling, regardless of whether the polymer is in an unswollen or swollen state, that is, if a swellable polymer has come into contact with water is present as an already swollen polymer, it is still considered as a "swellable polymer" within the meaning of the invention.
- the superabsorbent polymer is or comprises polyacrylate.
- the monomer content is in particular more than 70, for example more than 80 or 95 percent by weight of acrylic acid and / or a salt thereof (based on the total weight of the polyacrylate).
- the polyacrylate may be present as a homopolymer, copolymer or block polymer.
- the polyacrylate is preferably present as a partially neutralized polymer, in particular the degree of neutralization should be between 20% and 90%, more preferably between 45% and 80%.
- the absorbent body comprises a mixture of polyacrylate particles, wherein the particle mixture contains polyacrylate particles of different sizes, characterized in that the particle mixture a) contains 5 to 100% by weight, preferably 5 to 98 wt .-%, particles having a particle size x with x ⁇ 300 ⁇ , and b) 0 to 95 wt .-%, preferably 2 to 95 wt .-%, particles having a particle size x with x> 300 ⁇ , contains.
- the particle size is determined in the context of the present invention analogously to ED ANA 420.2-02, wherein the sieves (diameter 200 mm) have the appropriate hole sizes.
- sieves with other hole sizes such as 125 ⁇ , 160 ⁇ , 630 ⁇ , 900 ⁇ , and 1500 ⁇ ⁇ can be used.
- dry polyacrylate particles having a moisture content of less than 10% by weight of water, based on the total weight of the particles, are used, the moisture content being determined according to EDANA 450.2-02.
- the absorbent body may further comprise a nonwoven fabric.
- the nonwoven can serve as a carrier material for the swellable polymer.
- the swellable polymer according to the invention may preferably be applied or incorporated on a nonwoven as carrier material.
- These Arrangement is preferably part of the absorbent body or forms the absorbent body.
- the absorbent is preferably part of the wound dressing.
- the nonwoven is preferably a hydrophilic fiber material.
- the fibers of the hydrophilic fiber material may be, for example, water-insoluble fibers of cellulose, e.g. largely delignified engineering pulp fibers, e.g. Wood pulp fibers, preferably with a fiber length of ⁇ 5 mm or include.
- the nonwoven may also contain or consist of hydrophilic fiber material of regenerated cellulose, carboxymethylcellulose, carboxyethylcellulose, hydroxymethylcellulose or hydroxyethylcellulose.
- It may also be based on or consist of a mixture of fibers of cellulose, regenerated cellulose, carboxymethylcellulose, carboxyethylcellulose, hydroxymethylcellulose or hydroxyethylcellulose and thermoplastic fibers, for example of polyethylene, polypropylene or polyester.
- the swellable or superabsorbent polymer is preferably distributed in the form of particles in the web.
- the absorbent body comprises at least one superabsorbent polyacrylate and a nonwoven which comprises a mixture of cellulose fibers and polypropylene fibers or is based on such a mixture.
- the fleece can serve as a carrier material.
- the fibers can be processed into a layer together with particles or fibers of the superabsorbent polymer in a so-called airlaid process.
- the absorbent body is a wrapped airlaid comprising a superabsorbent polyacrylate, cellulosic and polypropylene fibers.
- the absorbent body is subjected to a solution.
- the application is preferably carried out to saturation and preferably with an aqueous solution which swells the swellable or superabsorbent material and turns it into a gelatinous state.
- the aqueous solution is preferably saline.
- the absorbent body can be acted upon, for example, with at least 600 weight percent, at least 800 weight percent, or at least 1000 weight percent of an aqueous solution, based on the weight of the dry absorbent body.
- the absorbent body is preferably applied with less than 5000 percent by weight, for example less than 3500 percent by weight, for example less than 2500 percent by weight, of an aqueous solution.
- the absorbent body contains that amount of an aqueous activation solution which corresponds to its maximum absorption capacity for Ringer's solution.
- the maximum uptake capacity for Ringer's solution can be determined according to the aforementioned test method WSP 240.2 (05), but a) instead of the saline solution used in WSP 240.2 (05) Ringer solution is used and b) instead of the sealed in a shell test substance ("Bag" according to Section 6.1 of WSP 240.2 (05)) of the absorbent body according to the invention is used.
- the maximum absorption capacity corresponds to the gravimetrically determined weight difference between the dry absorbent body and the activated absorbent body, whereby a deviation of the weight difference by 15% is included upwards or downwards.
- the aqueous solution is a synthetic solution and does not contain body fluids or body-separated fluids.
- the aqueous solution contains more than 50, eg more than 70, more than 80, more than 90 or 100 volume percent water. It can contain at least 5 mmol / l of sodium ions, at least 0.1 mmol / l of potassium ions, at least 0.1 mmol / l of calcium ions and / or at least 5 mmol / l of chloride ions.
- the aqueous solution contains further inorganic cations and / or anions, optionally organic anions, and optionally additions of bioorganic compounds.
- the pH is preferably 4 to 9. The viscosity at 20 ° C.
- the aqueous solution is a Ringer's solution.
- a Ringer's solution is meant an approximately to the blood iso-osmotic synthetic solution comprising sodium chloride, potassium chloride and calcium chloride dissolved in distilled water.
- the Ringer solution preferably contains 147 mmol / l sodium ions, 4.0 mmol / l potassium ions, 3.0 mmol / l calcium ions and 157 mmol / l chloride ions, whereby a deviation of the respective ion concentration from the stated value by 5% is possible ,
- an advantage of the applied absorbent solution is that immediately after the start of therapy, the wound is kept in a moist environment and does not dry out, which promotes the healing of wounds.
- the absorbent body for example as an alternative or in addition to the aqueous solution described above, an antimicrobial Include substance.
- the antimicrobial substance is or comprises a substance with antimicrobial activity, which is present in cationic form at pH values of from 4 to 7.5, for example substances having amino or imino groups.
- the cationic antimicrobial substance can be antimicrobially active metal cations, in particular silver cations, for example a complex of l-vinyl-2-pyrrolidone with silver cations.
- Particularly suitable cationic substances with antimicrobial action are biguanide derivatives such as chlorhexidine or polybiguanides, such as polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB) or polyethylene hexamethylene biguanides (PEHMB).
- biguanide derivatives such as chlorhexidine or polybiguanides, such as polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB) or polyethylene hexamethylene biguanides (PEHMB).
- PEB polyethylene biguanide
- PTMB polytetramethylene biguanide
- PEHMB polyethylene hexamethylene biguanides
- a particularly preferred polybiguanide is polyhexamethylene biguanide (PHMB or polyhexanide).
- polyguanidines such as polyhexamethyleneguanidines (PHMG), N-octyl-l - [10- (4-octyliminopyridin-1-yl) decyl] pyridin-4-imine (octenedin), quaternary ammonium compounds such as, for example, benzalkonium chloride or cetylpyridinium chloride, triazines such as, for example, 1- (3-chloroallyl) -3,5,7-triaza-1-azoniaadamantane chloride or the ammonium compound taurolidine.
- PHMG polyhexamethyleneguanidines
- quaternary ammonium compounds such as, for example, benzalkonium chloride or cetylpyridinium chloride
- the wound dressing according to the invention can also contain a wound contact layer and an evaporation-inhibiting backing layer.
- the wound dressing comprises
- the wound contact layer (i) is preferably a partially and / or structured applied, atraumatic coating.
- the coating can be applied directly to the absorbent body. Preferably, it is applied to a suction body, which is surrounded by the textile cover described above.
- the coating is preferably a silicone coating, wherein the coating may be, for example, porous and formed by a plurality of relatively thin strips or lines or island-shaped areas which may be separated from each other by uncoated areas. In these uncoated areas, the wound-facing side of the absorbent body may be exposed to the wound.
- the atraumatically acting coating can thus form a supernatant, whereby on the one hand a gluing of the absorbent body with wound tissue can be prevented and on the other hand a certain small distance between the wound-facing side of the absorbent body and the Wound tissue can be retained.
- the porous shell layer material can remain open three-dimensionally and provide or maintain less resistance to fluid passage in both directions over the useful life of the wound dressing.
- the wound-facing side of the absorbent body can be covered by a film, preferably a plastic film.
- the film is preferably substantially germ and waterproof and thus provides improved protection against evaporation.
- Wound dressing can be applied to a wound or used to stamp out deep wounds.
- the present invention is particularly advantageous when the wounds are burn wounds, wounds resulting from mechanical trauma, a wound resulting from the action of chemicals, a wound caused by a metabolic disorder, a wound caused by a circulatory disturbance, or a wound caused by a pressure ulcer wound acts.
- treatment 1 included 8 days of negative pressure therapy
- treatment 2 included a first treatment session with 4 days of negative pressure therapy, followed immediately by a second treatment session with 4 days of therapy in wet or damp Milieu.
- treatment 3 included a first therapy session with 6 days of negative pressure therapy, followed immediately by a second therapy session with 2 days of therapy in a damp or moist wet environment.
- the TenderWet ® Plus product (Paul Hartmann AG) was used as wound dressing for the second therapy section, for the negative pressure therapy were polyurethane film (Hydrofilm, Paul Hartmann AG) as covering material (a) and open-cell foam as wound dressing (c) (Vivanomed ® , Paul Hartmann AG) together with commercial adapter, hose (fluid communication means b) and vacuum device used.
- FIG. 1 shows that in the treatments B2 according to the invention (4 days underpressure + 4 days moist medium) and B3 (6 days underpressure + 2 days moist medium) the formation of granulation tissue is considerable compared to a negative pressure Bl of the same duration (8 days) has improved.
- FIG. 2 shows that in the treatments B2 according to the invention (4 days underpressure + 4 days moist medium) and B3 (6 days underpressure + 2 days moist medium), the neo-vascularization improves compared to a negative-pressure therapy B1 of the same duration (8 days) Has. A significant improvement in the stimulation of neovascularization could be achieved.
- FIG. 3 shows that in the treatments B2 according to the invention (4 days underpressure + 4 days moist medium) and B3 (6 days underpressure + 2 days moist medium) the formation of fibroblasts improves compared to a negative pressure Bl of the same duration (8 days) Has. A significant increase in fibroblast density could be achieved.
- wound exudate was obtained from chronic wounds (Eming et al., 2008). The amount corresponding to 50 micrograms of total protein was mixed with 100 mg FAVOR ® PAC 300 superabsorbent incubated (pre-swollen to saturation with Ringer's solution) for 2 hours.
- the present invention relates inter alia to the following aspects or embodiments:
- a product for use in the therapeutic treatment of wounds on the human or animal body comprising a device for the negative pressure therapy of wounds, characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device, and a subsequent second therapy section, in which the therapeutic treatment is carried out using a wound dressing without generating a negative pressure, wherein the wound dressing comprises an absorbent which comprises a swellable polymer, in particular a superabsorbent polymer.
- a product for use in the therapeutic treatment of wounds on the human or animal body comprising a wound dressing, and wherein the wound dressing comprises an absorbent body, the swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first treatment section, in which negative pressure therapy is performed by means of a device for negative pressure therapy of wounds, and a subsequent second therapy section, in which the therapeutic treatment using the wound dressing is performed without generating a negative pressure.
- a product for use in the therapeutic treatment of wounds on the human or animal body comprising a device for negative pressure therapy of wounds and a wound dressing
- the wound dressing comprises an absorbent body comprising a swellable polymer, in particular a superabsorbent polymer , characterized in that the therapeutic treatment comprises a first therapy section, in which negative pressure therapy is performed by means of the device, and a subsequent second therapy section, in which the therapeutic treatment is performed using the wound dressing without generating a negative pressure.
- the first treatment section ends, for example, with decay or completion of the inflammatory phase.
- the first part of the therapy for example, covers a period of 1 to 8 days.
- the second therapy section begins, for example, during or immediately after the inflammatory phase.
- the second therapy section extends, for example, over a period of 1 to 8 days.
- the absorbent body comprises, for example, a liquid-permeable, textile shell and arranged therein a superabsorbent polymer.
- the wound dressing comprises, for example: i) atraumatic wound contact layer, ii) absorbent body, and iii) preferably evaporation-inhibiting film layer on the side facing away from the wound.
- the absorbent body includes, for example, a non-woven, which contains, for example, cellulose fibers.
- the absorbent body can be applied with a solution, preferably Ringer's solution.
- the absorbent body may comprise an antimicrobial substance.
- the apparatus for performing negative pressure wound therapy includes, for example, (a) an air-impermeable cover material for hermetically sealing the wound and wound environment, forming a wound space, (b) means for providing fluid communication between the wound space and an outside of the cover material Vacuum source, so that a negative pressure in the wound space can be produced, and liquids are sucked from the wound space, (c) a wound dressing, which allows a substantially uniform distribution of negative pressure in the wound space, preferably a wound dressing containing open-cell foam, in particular open-cell polyurethane foam ,
- a wound dressing in the therapeutic treatment of wounds on the human or animal body, wherein the wound dressing comprises an absorbent body which comprises a swellable polymer, in particular a superabsorbent polymer, characterized in that the therapeutic treatment comprises a first therapy section in which Underpressure therapy is performed by means of a device for negative pressure therapy of wounds, and that the therapeutic treatment comprises a subsequent second treatment section, which is performed using the wound dressing without generating a negative pressure.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne de manière générale le traitement des plaies et en particulier des dispositifs ou systèmes de traitement de plaies. Une première partie du traitement consiste en une thérapie par pression négative, tandis que, dans une deuxième partie, le traitement se fait sans générer de pression négative. Le système comprend un pansement qui contient un polymère gonflant, en particulier un polymère superabsorbant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13722291.5A EP2900293A1 (fr) | 2012-09-25 | 2013-05-14 | Système de traitement de plaies |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12006687.3A EP2711033A1 (fr) | 2012-09-25 | 2012-09-25 | Système de traitement des plaies |
EP13722291.5A EP2900293A1 (fr) | 2012-09-25 | 2013-05-14 | Système de traitement de plaies |
PCT/EP2013/001417 WO2014048514A1 (fr) | 2012-09-25 | 2013-05-14 | Système de traitement de plaies |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2900293A1 true EP2900293A1 (fr) | 2015-08-05 |
Family
ID=46980694
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12006687.3A Withdrawn EP2711033A1 (fr) | 2012-09-25 | 2012-09-25 | Système de traitement des plaies |
EP13722291.5A Withdrawn EP2900293A1 (fr) | 2012-09-25 | 2013-05-14 | Système de traitement de plaies |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12006687.3A Withdrawn EP2711033A1 (fr) | 2012-09-25 | 2012-09-25 | Système de traitement des plaies |
Country Status (6)
Country | Link |
---|---|
US (1) | US9445948B2 (fr) |
EP (2) | EP2711033A1 (fr) |
CN (1) | CN104582749A (fr) |
HK (1) | HK1205021A1 (fr) |
RU (1) | RU2628061C2 (fr) |
WO (1) | WO2014048514A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102012025124A1 (de) | 2012-12-21 | 2014-06-26 | Paul Hartmann Ag | Saugkörper zur therapeutischen Behandlung einer Wunde mittels Unterdruck |
DE102012025125A1 (de) | 2012-12-21 | 2014-06-26 | Paul Hartmann Ag | Saugkörper zur therapeutischen Behandlung einer Wunde mittels Unterdruck |
DE102014106518A1 (de) | 2014-05-09 | 2015-11-12 | Paul Hartmann Ag | Schaumwundauflage für die Unterdrucktherapie |
EP3297697B1 (fr) | 2015-05-18 | 2022-05-11 | Smith & Nephew plc | Appareil de traitement des plaies par pression négative |
GB2557143B (en) * | 2015-08-13 | 2021-01-06 | Smith & Nephew Inc | Systems and methods for applying reduced pressure therapy |
WO2018150267A2 (fr) | 2017-02-15 | 2018-08-23 | Smith & Nephew Pte. Limited | Appareils de traitement de plaie par pression négative et leurs procédés d'utilisation |
US11389582B2 (en) | 2017-09-29 | 2022-07-19 | T.J. Smith And Nephew, Limited | Negative pressure wound therapy apparatus with removable panels |
GB201813282D0 (en) | 2018-08-15 | 2018-09-26 | Smith & Nephew | System for medical device activation and opertion |
GB201804347D0 (en) | 2018-03-19 | 2018-05-02 | Smith & Nephew Inc | Securing control of settings of negative pressure wound therapy apparatuses and methods for using the same |
WO2019199798A1 (fr) * | 2018-04-13 | 2019-10-17 | Kci Licensing, Inc. | Contrainte de compression et indicateur de distribution de pression négative pour pansement |
USD888225S1 (en) | 2018-04-30 | 2020-06-23 | Smith & Nephew Asia Pacific Pte. Limited | Pump and canister assembly for negative pressure wound therapy |
GB201806988D0 (en) | 2018-04-30 | 2018-06-13 | Quintanar Felix Clarence | Power source charging for negative pressure wound therapy apparatus |
EP3787704A1 (fr) | 2018-04-30 | 2021-03-10 | Smith & Nephew Asia Pacific Pte Limited | Systèmes et procédés de commande d'appareil de thérapie de plaie à pression négative à double mode |
GB201808438D0 (en) | 2018-05-23 | 2018-07-11 | Smith & Nephew | Systems and methods for determining blockages in a negative pressure wound therapy system |
RU2711570C1 (ru) * | 2018-10-30 | 2020-01-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПбГПМУ Минздрава России) | Способ остановки наружного кровотечения |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645081A (en) | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
ATE147253T1 (de) | 1992-10-22 | 1997-01-15 | Ivf Internationale Verbandstof | Plastisch verformbare kompresse |
US5465735A (en) * | 1994-12-01 | 1995-11-14 | The Kendall Company | Wound dressing |
US6169223B1 (en) * | 1999-02-08 | 2001-01-02 | Internationale Verbandstoff Fabrik Schaffhausen | Compress for medical treatment |
US7361184B2 (en) * | 2003-09-08 | 2008-04-22 | Joshi Ashok V | Device and method for wound therapy |
US7531711B2 (en) * | 2003-09-17 | 2009-05-12 | Ossur Hf | Wound dressing and method for manufacturing the same |
GB0508528D0 (en) * | 2005-04-27 | 2005-06-01 | Smith & Nephew | SAI with macrostress |
US20110313373A1 (en) * | 2004-11-02 | 2011-12-22 | Birgit Riesinger | Device for the treatment of wounds using a vacuum |
DE202004017052U1 (de) * | 2004-11-02 | 2005-06-09 | Riesinger, Birgit | Vorrichtung zur Wundbehandlung unter Einsatz von Unterdruck |
US20070027414A1 (en) * | 2005-07-28 | 2007-02-01 | Integra Lifesciences Corporation | Laminar construction negative pressure wound dressing including bioabsorbable material |
WO2007051599A1 (fr) * | 2005-11-02 | 2007-05-10 | Birgit Riesinger | Corps d'absorption destine a etre applique sur la surface cutanee d'un etre humain ou d'un animal |
AU2007212488B2 (en) * | 2006-02-07 | 2012-07-12 | Smith & Nephew Inc. | Surgical wound dressing |
GB0606661D0 (en) * | 2006-04-03 | 2006-05-10 | Brightwake Ltd | Improvements relating to dressings |
DE102006047041A1 (de) * | 2006-10-02 | 2008-04-10 | Birgit Riesinger | Flächenhafter Absorptionskörper |
RU62504U1 (ru) * | 2006-12-07 | 2007-04-27 | Юрий Павлович Савченко | Устройство для дренирования средостения |
US8377016B2 (en) * | 2007-01-10 | 2013-02-19 | Wake Forest University Health Sciences | Apparatus and method for wound treatment employing periodic sub-atmospheric pressure |
DE102008034363A1 (de) * | 2007-08-03 | 2009-02-05 | Birgit Riesinger | Wundpflegeartikel mit absorbierender Hülle |
WO2009021523A1 (fr) * | 2007-08-14 | 2009-02-19 | Coloplast A/S | Elément distributeur par pression d'une mousse à cellules fermées |
US20110054375A1 (en) | 2007-11-27 | 2011-03-03 | Hans Smola | Dressing comprising polyacrylate particles and use thereof |
GB0723874D0 (en) * | 2007-12-06 | 2008-01-16 | Smith & Nephew | Dressing |
WO2009086580A1 (fr) * | 2008-01-07 | 2009-07-16 | Cerulean Medical Pty Ltd | Dispositif de traitement à pression négative |
US8449508B2 (en) * | 2008-03-05 | 2013-05-28 | Kci Licensing, Inc. | Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site |
AU2009299453B2 (en) * | 2008-10-02 | 2014-10-02 | L.R.R.& D. Ltd. | Interface layer wound dressing |
WO2010093753A1 (fr) * | 2009-02-12 | 2010-08-19 | Perfuzia Medical, Inc. | Dispositifs et procédés pour la manipulation de la circulation dans le système circulatoire d'un patient |
SE533841C2 (sv) * | 2009-06-15 | 2011-02-01 | Moelnlycke Health Care Ab | Sårförband med hög vätskehanteringskapacitet |
DE102009031992A1 (de) * | 2009-07-06 | 2011-01-13 | Paul Hartmann Ag | Vorrichtung zur Unterdrucktherapie von Wunden |
US9358158B2 (en) * | 2010-03-16 | 2016-06-07 | Kci Licensing, Inc. | Patterned neo-epithelialization dressings, systems, and methods |
DE102010036371A1 (de) * | 2010-07-13 | 2012-01-19 | Birgit Riesinger | Wundpflegeartikel zur Wundbehandlung unter Einsatz von Unterdruck enthaltend Mikrofasern |
US20120046589A1 (en) | 2010-08-19 | 2012-02-23 | Axel Eckstein | Wound dressing comprising foam and ointment base for negative pressure therapy |
DE102010034819A1 (de) * | 2010-08-19 | 2012-02-23 | Paul Hartmann Ag | Verwendung eines Polyurethanschaumstoffs als Wundauflage in der Unterdrucktherapie |
TWI465263B (zh) * | 2010-12-10 | 2014-12-21 | Ind Tech Res Inst | 醫用敷料及使用該敷料之負壓治療裝置 |
CN102058932B (zh) * | 2010-12-20 | 2013-03-06 | 惠州市华阳医疗电子有限公司 | 负压治疗系统的负压控制装置 |
-
2012
- 2012-09-25 EP EP12006687.3A patent/EP2711033A1/fr not_active Withdrawn
-
2013
- 2013-05-14 CN CN201380043812.8A patent/CN104582749A/zh active Pending
- 2013-05-14 EP EP13722291.5A patent/EP2900293A1/fr not_active Withdrawn
- 2013-05-14 WO PCT/EP2013/001417 patent/WO2014048514A1/fr active Application Filing
- 2013-05-14 RU RU2015110123A patent/RU2628061C2/ru not_active IP Right Cessation
- 2013-09-24 US US14/034,709 patent/US9445948B2/en not_active Expired - Fee Related
-
2015
- 2015-06-17 HK HK15105747.8A patent/HK1205021A1/xx unknown
Non-Patent Citations (2)
Title |
---|
None * |
See also references of WO2014048514A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014048514A1 (fr) | 2014-04-03 |
RU2015110123A (ru) | 2016-11-20 |
EP2711033A1 (fr) | 2014-03-26 |
HK1205021A1 (en) | 2015-12-11 |
CN104582749A (zh) | 2015-04-29 |
US20140088527A1 (en) | 2014-03-27 |
US9445948B2 (en) | 2016-09-20 |
RU2628061C2 (ru) | 2017-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2900293A1 (fr) | Système de traitement de plaies | |
EP3139877B2 (fr) | Pansement en mousse pour traitement sous vide | |
EP2762177B1 (fr) | Dispositif de traitement par dépressurisation de plaies | |
WO2009019227A2 (fr) | Article pour le soin des plaies, présentant des polymères super-absorbants sous forme de fibres et/ou de fils | |
EP2635244B1 (fr) | Pansement pour plaie comprenant une couche de biocellulose et équipé pour adsorber des bactéries | |
WO2009019229A2 (fr) | Article pour le soin des plaies, présentant au moins une couche de polymères super-absorbants et une couche de mousse souple | |
WO2010026251A1 (fr) | Article pour le soin des plaies contenant une proportion de fibres naturelles modifiées ou de fibres synthétiques | |
DE102008037888A1 (de) | Wundpflegeartikel, aufweisend Textilbänder mit Fasern mit gelbildenden Eigenschaften sowie Fasern mit nicht gelbildenden Eigenschaften | |
WO2009019224A2 (fr) | Article pour le soin des plaies avec enveloppe absorbante | |
DE102007049430A1 (de) | Wundpflegeartikel, aufweisend mindestens einen Anteil an stützenden Fasern und einen Anteil an hydroaktiven Polymeren | |
WO2018115257A1 (fr) | Hydrogels aqueux pour le traitement de plaies | |
EP2934409A1 (fr) | Corps d'aspiration pour le traitement thérapeutique d'une plaie par dépression | |
DE102007063294A1 (de) | Wundauflage enthaltend superabsorbierende Polymere | |
EP2934410A1 (fr) | Corps d'aspiration pour le traitement thérapeutique d'une plaie par dépression | |
EP1799275B1 (fr) | Procede de production d'un pansement | |
EP2900287A1 (fr) | Polymère gonflant destiné à être utilisé dans le traitement thérapeutique | |
DE102007049428A1 (de) | Wundpflegeartikel, aufweisend mindestens eine Lage aufweisend superabsorbierende Polymere, sowie eine Lage aufweisend einen Weichschaumstoff | |
EP4134107A1 (fr) | Pansement doté d'une couche d'hydrogel et d'une couche de contact avec la plaie comprenant de l'acide hyaluronique | |
EP3842075B1 (fr) | Pansement contenant du siloxane | |
DD231987B5 (de) | Verfahren zur herstellung eines nicht resorbierbaren flachmaterials | |
WO2009019226A2 (fr) | Article pour le soin des plaies comportant un doublage immédiatement adjacent | |
EP2623136A2 (fr) | Couche membranaire à perméabilité variable à base de carragénane ou de chitosan en tant que pansements |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150303 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20170213 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20181201 |